ReviewInternational journal of molecular sciences2024
Oxidized Low-Density Lipoprotein and Its Role in Immunometabolism.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Gut Microbiota and Atherosclerotic Plaque Instability: Cellular and Molecular Mechanisms.International journal of molecular sciences · 2026Review
- Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma.Nature communications · 2026Article
- β-Glucans,Journal of fungi (Basel, Switzerland) · 2026Review
- Disruption of upstream ox-LDL signaling and HSP90-mediated NLRP3 stability protects against experimental steatohepatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The essential role of hydrogen gas recycling by gut microbes in reducing deuterium load in host mitochondria: is trimethylamine oxide a deuterium sensor?Metabolomics : Official journal of the Metabolomic Society · 2026Review
- Microbiota-Gut-Brain Axis Disruption, Neuroinflammation, and Potential Antioxidant-Based Treatments in Metabolic Diseases.Antioxidants (Basel, Switzerland) · 2026Review
- The Signal in the Extreme: A Systematic Outlier Framework Identifies Discrete Immunometabolic Subtypes in Human and Cellular Models.Medical sciences (Basel, Switzerland) · 2026Article
- From damage signals to immune modulators: oxidized lipids in immunometabolic inflammation.Journal of lipid research · 2026Review
- Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies.Frontiers in cardiovascular medicine · 2026Review
- The impact of metabolic syndrome and triglyceride-glucose index on the risk of in-stent restenosis after percutaneous coronary intervention: a retrospective study.Frontiers in cardiovascular medicine · 2026Article
- Small dense LDL: An underestimated driver of atherosclerosis (Review).Molecular medicine reports · 2025Review
- Correlations Between Immuno-Inflammatory Biomarkers and Hematologic Indices Stratified by Immunologic SNP Genotypes.Journal of clinical medicine · 2025Article
- Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy.Current opinion in lipidology · 2025Review
- Analysis and validation of hub genes for atherosclerosis and AIDS and immune infiltration characteristics based on bioinformatics and machine learning.Scientific reports · 2025Article
- Effect of Propolis Extracts on OxLDL and LOX-1 Levels in ApoE Knockout Mice Fed a High Fat Diet.Life (Basel, Switzerland) · 2025Article
- Metabolic Syndrome-Associated Erectile Dysfunction: Multiple Vascular Endothelial Dysfunction Mechanisms and Potential Therapeutic Targets.International journal of biological sciences · 2025Review
- Mechanism of salvianolic phenolic acids and hawthorn triterpenic acids combination in intervening atherosclerosis: network pharmacology, molecular docking, and experimental validation.Frontiers in pharmacology · 2025Article
- Resistin in cardiac diseases: from molecular mechanisms to clinical implications.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Modified cholesterols such as oxidized low-density lipoprotein (OxLDL) contribute to atherosclerosis and other disorders through the promotion of foam cell formation and inflammation. In recent years, it has become evident that immune cell responses to inflammatory molecules such as OxLDLs depend on cellular metabolic functions. This review examines the known effects of OxLDL on immunometabolism and immune cell responses in atherosclerosis and several other diseases. We additionally provide context on the relationship between OxLDL and aging/senescence and identify gaps in the literature and our current understanding in these areas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.